The Transparency Commission of the French National Health Authority issued a positive opinion regarding the reimbursement and hospital listing of Iluvien by the French National Health Insurance, according to a news release.
Under the Affection de Longue Duree program for severe chronic diseases, patients in France will be fully reimbursed for the cost of Iluvien (sustained-release fluocinolone acetonide, Alimera Sciences) for the treatment of chronic diabetic macular edema that is unresponsive to available therapies.
Alimera next will work with the Comite Economique des Produits de Sante to establish a price and potential reimbursement conditions for Iluvien in France.
The U.K., France, Austria, Portugal, Spain and Germany have granted national licenses for Iluvien. The treatment has not been approved by the U.S. Food and Drug Administration.